Pediatric Hypomelanosis of Ito 

  • Author: Camila K Janniger, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: May 16, 2011
 

Background

Hypomelanosis of Ito (HI) syndrome is characterized by the presence of whirled hypochromic skin lesions often associated with systemic manifestations. Ito first introduced the syndrome 1951.[1] In 1967, Hamada et al confirmed the association between the skin lesions and systemic abnormalities, including mental retardation.[2] Finally, Pascual-Castroviejo et al delineated the full spectrum of associated neurological abnormalities in a systematic study of the largest series published.[3]

Incontinentia pigmenti (IP) achromians is another term for this syndrome; however, because no true IP (melanin absent in the epidermis and present in the dermis) is present in the skin specimens, hypomelanosis of Ito syndrome has become the preferred name.

In 1992, Ruiz-Maldonado and associates established some diagnostic criteria for hypomelanosis of Ito syndrome.[4] Nonetheless, Ruiz-Maldonado et al's criteria link the diagnosis to the presence of systemic nondermatological (eg, CNS, skeletal) or chromosomal abnormalities. These criteria exclude patients with only dermatological manifestations. Patients with skin manifestations suggestive of hypomelanosis of Ito with and without systemic alterations have been described in the same family, demonstrating that hypomelanosis of Ito syndrome’s systemic involvement can vary. Studies that do not include systemic manifestations as diagnostic criteria for hypomelanosis of Ito reported that approximately 30-74% of patients with typical hypomelanosis of Ito skin lesions do not have nondermatological pathology.

Next

Pathophysiology

The pathogenesis of hypomelanosis of Ito syndrome is strongly linked to its genetics. A karyotype analysis survey was performed on 115 patients and revealed chromosomal anomalies in 60 (52%).[5] Many patients have a chromosomal mosaic pattern, often leading to the generation of 2 cell lineages, which produce patterns of hypopigmented and hyperpigmented skin. X-chromosome alterations are not unusual in hypomelanosis of Ito syndrome, and recent evidence points to X-chromosome inactivation, activation, and mosaicism as the main causes of these different patterns of cell behavior in the skin.

Perhaps this can also be found in other tissues, such as the fundus (tessellated or radial pigmentation of the fundi), iris (hypopigmentation), and the brain (areas with abnormal cell morphology and neuroblast migration side by side with normal patterns). Karyotyping the blood cells may not be diagnostic; a skin biopsy for fibroblasts may be necessary to detect the hypomelanosis of Ito–related chromosomal anomalies.

Despite recent advances, the genetic substrate for hypomelanosis of Ito syndrome is far from homogenous and is not completely understood. A wide range of chromosomal abnormalities may be observed, including balanced X-autosome translocations, supernumerary X-chromosome ring fragment, ring chromosome 10, mosaic triploidy, mosaic trisomies (8, 13, 14, 18, 22), mosaic translocations, and mosaic deletions. Autosomal deletions and duplications may involve chromosomes 7, 12, 13, 14, 15, and 18. The pattern of chromosomal aberrations and the polymorphic nature of this disease have led some to believe that hypomelanosis of Ito syndrome is a descriptive term rather than a true syndrome.

A familial form of hypomelanosis of Ito syndrome is noted; however, less than 3% of the patients have a family history of hypomelanosis of Ito–type skin lesions. Although hypomelanosis of Ito syndrome is most commonly a de novo occurrence, familial cases appear to be transmitted as an autosomal dominant trait. Approximately 10% of the patients report a family history of seizures or epilepsy, but the phenotypic expression varies; therefore, pigmentary changes may be the only clue to the genetic basis.

A cutaneous ultrastructural study that shows abnormal nerve termination in close proximity to basal keratinocytes, degenerated melanocytes, premelanosomes, and Langerhans cells has suggested that this finding may be important in the pathogenesis of hypomelanosis of Ito.[6]

Previous
Next

Epidemiology

Frequency

International

To date, epidemiological data on this syndrome are limited. It appears to be the third most common neurocutaneous disease, second only to neurofibromatosis and tuberous sclerosis. In a pediatric neurology service in Spain, 1 in 600-700 patients referred was diagnosed with hypomelanosis of Ito syndrome. It is diagnosed in 1 of every 7805 general pediatric outpatient visits, 1 of every 790 pediatric dermatology clinic visits, and 1 of every 2983 children in a general pediatric service.[3] Approximately three fourths of the patients with typical skin lesions have systemic manifestations.

Sex

Male-to-female ratios vary. In earlier series, the male-to-female ratio was reported to be 1:2.5. However, in larger and more recent series, the male-to-female ratio was 1:1.2. The severity of systemic manifestations appears to be similar in both sexes.

Age

Data in relation to age of diagnosis are usually reported in regard to the skin manifestations of hypomelanosis of Ito syndrome. Typical skin lesions are initially demonstrated during the first year of life in as many as 70% of patients; they are noticeable at birth in 54% of patients. Rarely, lesions are not visible until mid childhood.

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

Camila K Janniger, MD  Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Coauthor(s)

Marcio Sotero de Menezes, MD  Associate Professor, Department of Neurology, Division of Pediatric Neurology, Children's Hospital of Seattle, University of Washington School of Medicine

Marcio Sotero de Menezes, MD is a member of the following medical societies: American Academy of Neurology and American Epilepsy Society

Disclosure: Novartis Salary Speaking and teaching; Cyberonics Salary Speaking and teaching; Athena diagnostics Salary Speaking and teaching

Specialty Editor Board

Kevin P Connelly, DO  Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University School of Medicine; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center

Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Merrily P M Poth, MD  Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences

Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Ito M. A singular case of naevus depigmentosus systematicus bilateralis. Jpn J Dermatol. 1951;61:31-2.

  2. Hamada T, Saito T, Sugai T, Morita Y. "Incontinentia pigmenti achromians (Ito)". Arch Dermatol. Dec 1967;96(6):673-6. [Medline].

  3. Pascual-Castroviejo I, Lopez-Rodriguez L, de la Cruz Medina M, Salamanca-Maesso C, Roche Herrero C. Hypomelanosis of Ito. Neurological complications in 34 cases. Can J Neurol Sci. May 1988;15(2):124-9. [Medline].

  4. Ruiz-Maldonado R, Toussaint S, Tamayo L, Laterza A, del Castillo V. Hypomelanosis of Ito: diagnostic criteria and report of 41 cases. Pediatr Dermatol. Mar 1992;9(1):1-10. [Medline].

  5. Sybert VP. Hypomelanosis of Ito: a description, not a diagnosis. J Invest Dermatol. Nov 1994;103(5 Suppl):141S-143S. [Medline].

  6. Palungwachira P, Palungwachira P. Incontinentia pigmenti achromians of Ito: an ultrastructural study. J Med Assoc Thai. Feb 2006;89(2):253-7. [Medline].

  7. Degerliyurt A, Kantar A, Ceylaner S, Aysun S. Hypomelanosis of Ito and Sturge-Weber Syndrome Without Facial Nevus: An Association or a New Syndrome?. Pediatr Neurol. May 2009;40(5):395-397. [Medline].

  8. Glover MT, Brett EM, Atherton DJ. Hypomelanosis of Ito: spectrum of the disease. J Pediatr. Jul 1989;115(1):75-80. [Medline].

  9. Pascual-Castroviejo I, Roche C, Martinez-Bermejo A, et al. Hypomelanosis of ITO. A study of 76 infantile cases. Brain Dev. Jan 1998;20(1):36-43. [Medline].

  10. Park JM, Kim HJ, Kim T, Chae HW, Kim DH, Lee MG. Sexual precocity in hypomelanosis of Ito: mosaicism-associated case report and literature review. Int J Dermatol. Feb 2011;50(2):168-74. [Medline].

  11. Gatter N, Hoppe B, Nutzenadel F, Waldherr R, Querfeld U. A cutaneous disease with multisystem involvement: hypomelanosis of Ito may be associated with proteinuria, focal segmental glomerulosclerosis and end-stage renal disease. Nephrol Dial Transplant. Mar 8 2007;[Medline].

  12. Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. Oct 2000;15(10):652-9. [Medline].

  13. Sybert VP, Pagon RA, Donlan M, Bradley CM. Pigmentary abnormalities and mosaicism for chromosomal aberration: association with clinical features similar to hypomelanosis of Ito. J Pediatr. Apr 1990;116(4):581-6. [Medline].

  14. Rosman NP. Incontinentia Pigmenti. In: Gomez MR, ed. Neurocutaneous Diseases: A Practical Approach. Boston: Butterworths; 1987:294-300.

  15. Huggins RH, Schwartz RA, Janniger CK. Vitiligo. Acta Dermatovenerol Alp Panonica Adriat. Dec 2005;14(4):137-42, 144-5. [Medline].

  16. Huggins RH, Janusz CA, Schwartz RA. Vitiligo: a sign of systemic disease. Indian J Dermatol Venereol Leprol. Jan-Feb 2006;72(1):68-71. [Medline].

  17. Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc. Apr 2008;13(1):20-4. [Medline].

  18. Ardinger HH, Bell WE. Hypomelanosis of Ito. Wood's light and magnetic resonance imaging as diagnostic measures. Arch Neurol. Aug 1986;43(8):848-50. [Medline].

  19. Battistella PA, Peserico A, Bertoli P, et al. Hypomelanosis of Ito and hemimegalencephaly. Childs Nerv Syst. Nov 1990;6(7):421-3. [Medline].

  20. Berg B. Neurocutaneous syndromes: Phakomatoses and allied conditions. In: Swaiman K, ed. Pediatric Neurology: Principles and Practice. 2nd ed. 1994:1045-1069.

  21. Berg BO. Unusual neurocutaneous syndromes. Neurol Clin. Feb 1985;3(1):165-78. [Medline].

  22. Chevalier C, Colon S, Faraj G, et al. [Glomerulopathy and hypomelanosis of Ito]. Nephrologie. 1997;18(4):125-7. [Medline].

  23. Fonseca E, Contreras F, Soto J. Marcadores cutos de los sromes neuroectodermicos. In: Pascual-Castroviejo I, Barcelona JR, eds. Transtornos Neuroectodermicos. 1989:73-84.

  24. Fryburg JS, Lin KY, Matsumoto J. Abnormal head MRI in a neurologically normal boy with hypomelanosis of Ito. Am J Med Genet. Dec 11 1996;66(2):200-3. [Medline].

  25. Glab E, Barg E, Wikiera B. Hypomelanosis of Ito and precocious adrenarche in a girl. J Pediatr Endocrinol Metab. Mar 2006;19(3):283-4. [Medline].

  26. Hara M, Kozasa M, Mituisi Y. Ito Syndrome (Hypomelanosis of Ito) as a cause of intractable epilepsy. In: Pascual-Castroviejo I, Barcelona JR eds. Transtornos Neuroectodermicos. 1989:221-5.

  27. Neurocutaneous Disorders. In: Hurwitz S, ed. Clinical Pediatric Dermatology. 2nd ed. Philadelphia, Penn: WB Saunders; 1993:624-640.

  28. Ishikawa T, Kanayama M, Sugiyama K, Katoh T, Wada Y. Hypomelanosis of Ito associated with benign tumors and chromosomal abnormalities: a neurocutaneous syndrome. Brain Dev. 1985;7(1):45-9. [Medline].

  29. Jadotte YT, Janniger CK. Pityriasis alba revisited: perspectives on an enigmatic disorder of childhood. Cutis. Feb 2011;87(2):66-72. [Medline].

  30. Keng WT, Harewood L, Grace E, et al. A balanced reciprocal translocation in a case of hypomelanosis of Ito with confirmation of mosaicism using buccal cell interphase FISH. Am J Med Genet A. May 15 2006;140(10):1111-3. [Medline].

  31. Khandpur S, Minz A, Sharma VK. An unusual association of pigmentary mosaicism (hypomelanosis of Ito) with generalized hypertrichosis. Clin Exp Dermatol. May 2006;31(3):467-8. [Medline].

  32. Nehal KS, PeBenito R, Orlow SJ. Analysis of 54 cases of hypopigmentation and hyperpigmentation along the lines of Blaschko. Arch Dermatol. Oct 1996;132(10):1167-70. [Medline].

  33. Ono J, Harada K, Kodaka R, Ishida M, Okada S. Regional cortical dysplasia associated with suspected hypomelanosis of Ito. Pediatr Neurol. Oct 1997;17(3):252-4. [Medline].

  34. Pascual-Castroviejo I. Hypomelanosis of Ito. In: Gomez MR, ed. Neurocutaneous Diseases: A Practical Approach. Boston, MA: Butterworths; 1987:85-90.

  35. Pascual-Castroviejo I. Nevus Acro de Ito. In: Castro-Viejo I, ed. Neurologia Infantil. Madrid, Spain: Editorial Cientifico; 1983:678-680.

  36. Rafay MF, Al-Futaisi A, Weiss S, Armstrong D. Hypomelanosis of Ito and Moyamoya disease. J Child Neurol. Nov 2005;20(11):924-6. [Medline].

  37. Reese PD, Judisch GF. Hypomelanosis of Ito. Arch Ophthalmol. Aug 1986;104(8):1136-7. [Medline].

  38. Ross DL, Liwnicz BH, Chun RW, Gilbert E. Hypomelanosis of Ito (incontinentia pigmenti achromians)--a clinicopathologic study: macrocephaly and gray matter heterotopias. Neurology. Sep 1982;32(9):1013-6. [Medline].

  39. Rubin MB. Incontinentia pigmenti achromians. Multiple cases within a family. Arch Dermatol. Mar 1972;105(3):424-5. [Medline].

  40. Ruggieri M, Pavone L. Hypomelanosis of Ito: clinical syndrome or just phenotype?. J Child Neurol. Oct 2000;15(10):635-44. [Medline].

  41. Ruggieri M, Tigano G, Mazzone D, Tine A, Pavone L. Involvement of the white matter in hypomelanosis of Ito (incontinentia pigmenti achromiens). Neurology. Feb 1996;46(2):485-92. [Medline].

  42. Steiner J, Adamsbaum C, Desguerres I, et al. Hypomelanosis of Ito and brain abnormalities: MRI findings and literature review. Pediatr Radiol. Nov 1996;26(11):763-8. [Medline].

  43. Hypomelanosis of Ito. In: Sybert VP, ed. Genetic Skin Disorders. New York, NY: Oxford University Press; 1997:318-22.

  44. Sybert VP, Pagon RA. Hypomelanosis of Ito in a girl with plexus papilloma and translocation (X;17) [letter]. Hum Genet. Feb 1994;93(2):227. [Medline].

  45. Tagawa T, Futagi Y, Arai H, Mushiake S, Nakayama M. Hypomelanosis of Ito associated with hemimegalencephaly: a clinicopathological study. Pediatr Neurol. Sep 1997;17(2):180-4. [Medline].

  46. Urban J, Toruniowa B, Janniger CK, Czelej D, Schwartz RA. Incontinentia pigmenti (Bloch-Sulzberger syndrome): multisystem disease observed in two generations. Cutis. Nov 1996;58(5):329-36. [Medline].

  47. Urgelles E, Pascual-Castroviejo I, Roche C, et al. Arteriovenous malformation in hypomelanosis of Ito. Brain Dev. Jan-Feb 1996;18(1):78-80. [Medline].

  48. Weaver RG Jr, Martin T, Zanolli MD. The ocular changes of incontinentia pigmenti achromians (hypomelanosis of Ito). J Pediatr Ophthalmol Strabismus. May-Jun 1991;28(3):160-3. [Medline].

  49. Zajac V, Kirchhoff T, Levy ER, et al. Characterisation of X;17(q12;p13) translocation breakpoints in a female patient with hypomelanosis of Ito and choroid plexus papilloma. Eur J Hum Genet. Mar-Apr 1997;5(2):61-8. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.